^
Association details:
| Biomarker: | LDH elevation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
LDH levels as predictors of efficacy in second-line treatment for metastatic gastric cancer: The LINE study
Published date:
07/01/2020
Excerpt:
After progression to first-line treatment,
65 patients (69%) were treated with ramucirumab in association with paclitaxel or as a single-agent, while 29 (31%) received taxanes (10%) or fluoropyrimidine-based
chemotherapy regimens combined with irinotecan (21%)....At subgroup analyses, patients treated with ramucirumab-based regimens who had elevated baseline LDH levels had a trend towards worse PFS (HR 2.76, 95% CI 1.09-6.94, p¼0.031) (p of interaction 0.31) and OS (HR 4.29, 95% CI 1.59-11.51, p¼0.004) (p of interaction¼0.096).
Secondary therapy:
irinotecan; bisphosphonate bound paclitaxel
DOI:
10.1016/j.annonc.2020.04.348
